ZubrodC, SchneidermanM, FreiE, et al.: Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chronic Dis, 1960; 11:7–33.
2.
OkenMM, CreechRH, TormeyDC, et al.: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol, 1982; 5:649–655.
3.
ChengS, QureshiM, PullenayegumE, et al.Do patients with reduced or excellent performance status derive the same clinical benefit from novel systemic cancer therapies? A systematic review and meta-analysis. ESMO Open, 2017; 2:e000225.
4.
KawaguchiT, TakadaM, KuboA, et al.: Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: A comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol, 2010; 5:620–630.
5.
CareyMS, BaconM, TuD, et al.: The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer. Gynecol Oncol, 2008; 108:100–105.
6.
SleijferS, OualiM, van GlabbekeM, et al.: Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer, 2010; 46:72–83.
7.
BaldottoCS, CronembergerEH, de BiasiP, et al.: Palliative care in poor-performance status small cell lung cancer patients: Is there a mandatory role for chemotherapy?. Support Care Cancer, 2012; 20:2721–2727.
8.
Crosara TeixeiraM, MarquesDF, FerrariAC, et al.: The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4. Clin Colorectal Cancer, 2015; 14:52–57.
9.
Grajales-ÁlvarezR, Martin-AguilarA, SilvaJA, et al.: ECOG is as independent predictor of the response to chemotherapy, overall survival and progression-free survival in carcinoma of unknown primary site. Mol Clin Oncol, 2017; 6:643–650.
10.
PengMT, LiuCT, HungYS, et al.: Sequential assessments of the Eastern Cooperative Oncology Group Performance Scale enhance prognostic value in patients with terminally ill cancer receiving palliative care. Am J Hosp Palliat Care, 2016; 33:471–476.
11.
MagnusonA, BruinoogeSS, SinghH, et al.: Modernizing clinical trial eligibility criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group. Clin Cancer Res, 2021; 27:2424–2429.
12.
Abi JaoudeJ, KouzyR, MainwaringW, et al.: Performance status restriction in phase III cancer clinical trials. J Natl Compr Canc Netw, 2020; 18:1322–1326.
HannaNH, SchneiderBJ, TeminS, et al.: Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) Joint Guideline Update. J Clin Oncol, 2020; 38:1608–1632.
15.
MuchnikE, LohKP, StrawdermanM et al.: Immune checkpoint inhibitors in real-world treatment of older adults with non-small cell lung cancer. J Am Geriatr Soc, 2019; 67:905–912.
16.
SehgalK, GillRR, WidickP, et al.: Association of performance status with survival in patients with advanced non-small cell lung cancer treated with pembrolizumab monotherapy. JAMA Netw Open, 2021; 4.
17.
YangF, MarkovicSN, MolinaJR, et al.: Association of sex, age, and Eastern Cooperative Oncology Group Performance Status with survival benefit of cancer immunotherapy in randomized clinical trials: A systematic review and meta-analysis. JAMA Netw Open, 2020; 3.
18.
KhakiAR, LiA, DiamantopoulosLN, et al.: Impact of performance status on treatment outcomes; A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer, 2020; 126:1208–1216.
19.
PluvyJ, BrosseauS, NaltetC, et al.: Lazarus syndrome in nonsmall cell lung cancer patients with poor performance status and major leukocytosis following nivolumab treatment. Eur Respir J, 2017; 50:1700310.
20.
PietrantonioF, LoupakisF, RandonG, et al.: Efficacy and safety of immune checkpoint inhibitors in patients with microsatellite instability-high end-stage cancers and poor performance status related to high disease burden. Oncologist, 2020; 25:803–809.
21.
KimYJ, HuiD, ZhangY, et al.: Differences in performance status assessment among palliative care specialists, nurses, and medical oncologists. J Pain Symptom Manage, 2015; 49:1050–1058.
